von Willebrand factor (445-733)

reduced and recombinant form of von Willebrand factor (445-733) that antagonizes the platelet glycoprotein Ib receptor; fibrinogen receptor antagonist

Also Known As:

RG 12986; RG-12986; RG12986; vWF (Ser445-Val733)

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Blood Coagulation Factors: 5376
      - von Willebrand Factor: 6708
        von Willebrand factor (445-733): 2
- Peptides: 82426
  - Peptide Fragments: 373
    - von Willebrand factor (445-733): 2
Biological Factors: 2472
- Blood Coagulation Factors: 5376
  - von Willebrand Factor: 6708
    - von Willebrand factor (445-733): 2

Related Diseases

Thrombosis (Thrombus)

07/15/1996 - "At 1800 s-1 and 4 min of perfusion, platelet adhesion decreased from 63 +/- 7% for control, to 46 +/- 4% for 20 mg/kg RG12986, and to 29 +/- 5% for 4 mg/kg VCL, and the mean thrombus height dropped from 40 +/- 8 microns to 24 +/- 3 microns and 7.5 +/- 1 microns, respectively. "
09/01/1993 - "The extent of inhibition observed with RG12986 at a final concentration of 4 microM was similar to that obtained with the cell adhesion peptide RGDS at the concentration of 0.1 mM. The ability of the RG12986 fragment to inhibit platelet aggregation on ECM is in agreement with the concept that blockade of vWF-GPIb interaction may inhibit further events leading to activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex and subsequent thrombus formation."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Glycoproteins (Glycoprotein)